Remove 2016 Remove Compounding Remove Immunity
article thumbnail

TAR-200 Clears Tumors in 82% of Patients With BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer

Pharmacy Times

4 “We are at an exciting moment in history,” said Daneshmand, who has been researching this novel treatment since 2016. Rates of serious treatment-related adverse events were 5.9%, 5.8%, 15.1%, and 3.6% in cohort 2, cohort 4, cohort 1, and cohort 3, respectively. No treatment-related deaths occurred. 3 REFERENCES 1.

article thumbnail

FDA Moving to Nonanimal Testing Methodologies in Preclinical Research

Pharmacy Times

Historically, the FDA has required preclinical testing in animals to obtain safety and efficacy data for investigational new drugs (INDs) before they can begin clinical testing in humans. 3 More simply, the FDA is moving preclinical testing from in vivo animal models to in silico and in vitro methods.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Pharmacy Times

The 2016 World Health Organization classification of MCL recognizes 2 molecular subtypes that reflect divergent pathogenesis and clinical behavior 2 : Classical MCL is derived from naive B cells that lack somatic hypermutation in IGHV , do not transit through the germinal center, and express the SOX11 transcription factor.

article thumbnail

Pharmacists Push Forward: Innovative Clinical Solutions Highlighted at McKesson ideaShare 2025

Pharmacy Times

One study conducted in 2016-2017 found that 10% of new prescriptions for contraceptive pills and patches were written by pharmacists during that period. 1 Meredith also cited promising outcomes from states like Oregon.

article thumbnail

Lumateperone Submits Application for Schizophrenia Indication to FDA for Supplemental New Drug

Pharmacy Times

FDA for CAPLYTA® (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo. July 8, 2025. Nasrallah, H. Bossie, C. Hough, D., & & Turkoz, I. Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy.

article thumbnail

Zanubrutinib Linked to Lower Infection Risk Than Venetoclax Plus Obinutuzumab in Real-World CLL/SLL Study

Pharmacy Times

However, patients with CLL/SLL typically have a higher risk of serious infection due to their compromised immune systems, raising concerns about the association between CLL/SLL-directed therapies and serious infection risks.

article thumbnail

Invest a Few Minutes in Inhaler Counseling

Pharmacy Times

doi:10.1183/13993003.01794-2016 Leving MT, Kocks J, Bosnic-Anticevich S, Dekhuijzen R, Usmani OS. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J. 2017;49(2):1601794.